Journal: BMC Gastroenterology
Article Title: Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice
doi: 10.1186/s12876-026-04610-1
Figure Lengend Snippet: Effects of Tofo on the hepatic protein levels. A Hepatic protein levels of ACC, FASN, SREBP-1c, CD36, FATP2, CPT1a, FXR, and β-actin. B The protein levels were normalized relative to the expression of β-actin. Data are presented as mean ± SD ( n = 3 per group). Statistical analyses were performed using one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001, and “ns” non-significant
Article Snippet: The primary antibodies used in immunoblotting included antibodies against acetyl-CoA carboxylase (ACC) (#3676, Cell Signaling Technology, MA, USA), cluster of differentiation 36 (CD36) (#28109, Cell Signaling Technology), carnitine palmitoyltransferase 1a (CPT1a) (ab234111, Abcam), fatty acid synthase (FASN) (#3180, Cell Signaling Technology), fatty acid transport protein 2 (FATP2) (#78771, Cell Signaling Technology), farnesoid X receptor (FXR) (#72105, Cell Signaling Technology), and sterol regulatory element binding protein-1c (SREBP-1c) (sc-13551, Santa Cruz Biotechnology, TX, USA).
Techniques: Expressing